ZA200806362B - Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections - Google Patents

Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Info

Publication number
ZA200806362B
ZA200806362B ZA200806362A ZA200806362A ZA200806362B ZA 200806362 B ZA200806362 B ZA 200806362B ZA 200806362 A ZA200806362 A ZA 200806362A ZA 200806362 A ZA200806362 A ZA 200806362A ZA 200806362 B ZA200806362 B ZA 200806362B
Authority
ZA
South Africa
Prior art keywords
treatment
polyclonal antibody
respiratory syncytial
syncytial virus
virus infections
Prior art date
Application number
ZA200806362A
Other languages
English (en)
Inventor
Lantto Johan
Steinaa Lucilla
Koefoed Klaus
Lars S Nielsen
Nielsen Henriette Schjoenning
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of ZA200806362B publication Critical patent/ZA200806362B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200806362A 2006-03-06 2008-07-22 Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections ZA200806362B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600324 2006-03-06
US87471606P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
ZA200806362B true ZA200806362B (en) 2009-05-27

Family

ID=38230163

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806362A ZA200806362B (en) 2006-03-06 2008-07-22 Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Country Status (12)

Country Link
US (1) US20100040606A1 (cg-RX-API-DMAC10.html)
EP (1) EP2004686A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009528828A (cg-RX-API-DMAC10.html)
KR (1) KR20080113223A (cg-RX-API-DMAC10.html)
CN (1) CN101395182A (cg-RX-API-DMAC10.html)
AU (1) AU2007222798A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0708636A2 (cg-RX-API-DMAC10.html)
CA (1) CA2638833A1 (cg-RX-API-DMAC10.html)
IL (1) IL193386A0 (cg-RX-API-DMAC10.html)
MX (1) MX2008011280A (cg-RX-API-DMAC10.html)
WO (1) WO2007101441A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806362B (cg-RX-API-DMAC10.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
NZ578851A (en) 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
AU2008295248A1 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-RSV antibodies
BRPI0817257A2 (pt) * 2007-09-24 2015-06-16 Univ Vanderbilt Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
CN102265152A (zh) * 2008-10-06 2011-11-30 西福根有限公司 鉴定和选择用于组合药品的药物候选物
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
ES2568509T3 (es) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
CA2765949C (en) 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
EP2453903B1 (en) * 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes
BR112012007815A2 (pt) 2009-10-09 2018-03-20 Symphogen As quantificação multiplex de proteínas recombinantes em uma mistura por peptídeos de assinatura e espectrometria de massa.
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
EP2591000B1 (en) * 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP3561073A1 (en) * 2010-10-08 2019-10-30 President and Fellows of Harvard College High-throughput immune sequencing
EP2663334A4 (en) * 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
HK1201565A1 (en) 2011-10-21 2015-09-04 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3388535B1 (en) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
WO2013119419A1 (en) * 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
PT2831276T (pt) 2012-05-08 2016-07-26 Adaptive Biotechnologies Corp Composições e método para medição e calibração do viés de amplificação em reações pcr multiplex
TR201900694T4 (tr) * 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
EP2904111B1 (en) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014144495A1 (en) 2013-03-15 2014-09-18 Abvitro, Inc. Single cell bar-coding for antibody discovery
CN103196731A (zh) * 2013-04-18 2013-07-10 王刚平 用于鉴别乳腺肌上皮病变的多重染色试剂及其检测方法
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
CA2941612A1 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US10590483B2 (en) 2014-09-15 2020-03-17 Abvitro Llc High-throughput nucleotide library sequencing
CA2960925A1 (en) * 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
CN121021679A (zh) * 2014-10-15 2025-11-28 芝诺锡拉公司 具有降低的免疫原性的组合物
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
EP3498866B1 (en) 2014-11-25 2026-02-25 Adaptive Biotechnologies Corp. Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
WO2018052789A1 (en) * 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
BR112021009572A2 (pt) * 2018-11-30 2021-08-17 Csl Behring Ag métodos e composições para prevenção ou tratamento de exacerbações agudas com imunoglobulina policlonal
JP2022531113A (ja) 2019-04-30 2022-07-06 ギガジェン，インコーポレイティッド 組換えポリクローナルタンパク質およびその使用方法
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
JP2024508222A (ja) * 2021-01-29 2024-02-26 アムジエン・インコーポレーテツド 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法
CN113249333B (zh) * 2021-03-16 2023-06-02 贵州省人民医院 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767610A (en) * 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
EP0539522B1 (en) * 1990-07-19 1998-12-30 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5344640A (en) * 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU686113B2 (en) * 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE178906T1 (de) * 1994-08-25 1999-04-15 Stichting Inst Dierhouderij Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen
US5922344A (en) * 1995-02-10 1999-07-13 Abbott Laboratories Product for prevention of respiratory virus infection and method of use
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP2003525061A (ja) * 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
EP1334119B2 (en) * 2000-10-18 2018-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for modulating rsv infection and immunity
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
EA013225B1 (ru) * 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
US6821450B2 (en) * 2003-01-21 2004-11-23 Hewlett-Packard Development Company, L.P. Substrate and method of forming substrate for fluid ejection device
WO2004087062A2 (en) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP2008513540A (ja) * 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
WO2007065433A2 (en) * 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same

Also Published As

Publication number Publication date
KR20080113223A (ko) 2008-12-29
US20100040606A1 (en) 2010-02-18
IL193386A0 (en) 2011-08-01
JP2009528828A (ja) 2009-08-13
CN101395182A (zh) 2009-03-25
AU2007222798A1 (en) 2007-09-13
CA2638833A1 (en) 2007-09-13
EP2004686A1 (en) 2008-12-24
MX2008011280A (es) 2008-09-12
BRPI0708636A2 (pt) 2011-06-07
WO2007101441A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
IL193386A0 (en) Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
IL200330A0 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
ZA201000756B (en) Methods for recombinant manufacturing of anti-rsv antibodies
PL1951272T3 (pl) Zastosowanie lactobacillus do leczenia infekcji wirusowych
PH12013500952A1 (en) Oligosaccharide composition for treating acute respiratory tract infections
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
BRPI0915960A2 (pt) antígenos de polipeptídeos do vírus sincicial respiratório qimérico
ZA201100176B (en) Compounds and pharmaceutical compositions for the treatment of viral infections
SG10201800717UA (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
ZA201304117B (en) Compounds for treating respiratory syncytial virus infections
ZA201102112B (en) Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection
PL2018184T3 (pl) Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
DK2229409T3 (da) Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer
IL245348B (en) Compounds for the treatment of paramyxoviridae virus infections
IL195272A0 (en) Methods and compositions for the treatment of viral infections
GB2467491C (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies
IL221320A0 (en) Compounds for treating respiratory syncytial virus infections
DK1847256T3 (da) Antibakterielle sammensætninger til behandling af infektioner i de øvre og nedre luftveje
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
IL197783A0 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
BRPI0923569A2 (pt) anticorpo monoclonal anti-hcv como um medicamento para tratamento e prevenção de infecções por hcv
PL2132215T3 (pl) Związki do zapobiegania lub leczenia zakażeń wirusowych i sposoby ich stosowania
ZA200802934B (en) Use of lactobacillus for treatment of virus infections
HK1134825A (en) Recombinant antibodies for treatment of respiratory syncytial virus infections